Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...

Cancer cells that detach from a primary tumor can remain hidden in the body for years in a dormant state, avoiding immune ...

A vitamin A byproduct has been found to quietly disarm the immune system, allowing tumors to evade attack and weakening ...

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T ...

Among modern cancer therapies, immune checkpoint inhibitors (ICI) are among the most successful treatment methods. These ...

Cancer cells that have broken away from a primary tumor can lurk in the body for years in a dormant state, evading immune ...

An immunotherapy kept multiple myeloma at bay for over 80 percent of patients in a three-year clinical trial, and the FDA ...

Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...